Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jul 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ABC Survival trial is studying how different types of anesthesia used during brain surgery might affect the survival of patients with high-grade brain tumors, specifically glioblastoma multiforme (GBM). Previous research suggests that intravenous anesthesia (like propofol) may help slow down cancer progression and improve survival rates compared to gaseous anesthesia (like sevoflurane). This trial aims to see if using propofol can provide similar benefits for patients undergoing surgery for these aggressive tumors.
To participate, patients must be over 18 years old and are scheduled for elective brain surgery to remove a suspected high-grade tumor between July 2022 and December 2023. Those with certain conditions, like previous severe adrenal issues or specific types of tumors, will not be eligible. Participants in this study will help researchers understand how to better design future studies that could lead to improved treatment options for brain cancer patients. If you or a loved one is considering joining, you can expect to be closely monitored during and after the surgery, and your experience will contribute to important research in this field.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient presenting between Jul 1, 2022 and Dec 28, 2023 for elective procedure
- • 2. Males or females of \>18 years
- • 3. Patient will be undergoing primary craniotomy (with general anesthesia) for suspected high-grade primary glial brain tumor (WHO grade III and IV)
- Exclusion Criteria:
- • 1. Patients of pediatric age group and pregnant patients
- • 2. Patients previously diagnosed with severe adrenal dysfunction (over activity or insufficiency)
- • 3. Suspected low grade (grade I, II), glioma, tumors involving brainstem and optic tract, and as well as non-glial tumors (i.e. suspected brain metastasis)
- • 4. Awake craniotomies
- • 5. Any conditions that preclude postoperative MRI
- • 6. Motor evoked potential monitoring or any other intraoperative condition that renders choice of anesthetics affected.
- • 7. Recurrent GBM
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Tumul Chowdhury, MD
Principal Investigator
University Health Network, Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials